SEC Form 4 · accession 0001615774-16-006375
ANAVEX LIFE SCIENCES CORP. · AVXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher U Missling
Officer — President, CEO & Treasurer · Director
Period of report
Jul 5, 2016
Accepted (ET)
Jul 19, 2016 · 7:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314052
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.26 | Jul 5, 2016 | A | 379,625 | A | — | Jul 5, 2026 | Common Stock | 379,625 | 379,625 | D |
| Stock Option (Right to Buy)F2 | $7.06 | Jul 18, 2016 | A | 861,429 | A | — | Jul 18, 2026 | Common Stock | 861,429 | 861,429 | D |
Explanation of responses
- F1Pursuant to a First Amendment to the Employment Agreement between the Issuer and Dr. Christopher Missling (the "First Amendment") filed with the Securities and Exchange Commission on July 7, 2016, the Issuer issued to Dr. Missling options to purchase 379,625 shares of the Issuer's common stock with a grant date value of $2,000,000 as determined based on a Black Scholes formula, with such options to vest quarterly over a three-year period commencing on October 5, 2016.
- F2The Issuer amended the First Amendment to clarify the Board of Director's intention with respect to Dr. Missling's stock option grant and in connection therewith, the Issuer issued to Dr. Missling options to purchase 861,429 shares of the Issuer's common stock, with such options to vest quarterly over a three-year period commencing on October 18, 2016.